Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
Therapy for Ph-positive chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib results in achievement of high hematological and cytogenetic response rates. However, most patients with a complete cytogenetic response were found to have a minimal residual disease. Therefore the rol...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/748 |